IRADIMED CORP (IRMD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. IRADIMED Corporation develops, manufactures, and distributes MRI-compatible medical devices, including IV infusion pumps, patient vital signs monitoring systems, and ferromagnetic detection systems. The company operates as a single reporting segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $20.41 million | $17.93 million | $39.92 million | $35.53 million |
| Gross Profit | $15.95 million | $14.01 million | $30.80 million | $27.40 million |
| Gross Margin | 78.2% | 78.1% | 77.1% | 77.1% |
| Net Income | $5.77 million | $4.90 million | $10.46 million | $9.04 million |
| Diluted EPS | $0.45 | $0.38 | $0.82 | $0.71 |
| Cash & Equivalents | $53.0 million (as of June 30, 2025) | |||
| Working Capital | $68.6 million (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $12.04 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14% in Q2 and 12% YTD compared to 2024. Growth was driven by higher sales of IV infusion pumps, disposables, and extended warranty amortization.
- Geographic Mix: U.S. revenue grew 17% in Q2 to $18.2 million, while international revenue declined 8% to $2.2 million. Domestic sales now represent 89% of total revenue.
- Operating Expenses: Total operating expenses increased 9% in Q2. Sales and marketing expenses rose 15% due to higher commissions and payroll. R&D expenses increased 10% in Q2 due to the newly cleared MRidium 3870 system.
- Capital Expenditures: Investing cash outflows surged to $6.74 million YTD (vs. $1.75 million in 2024), primarily due to construction costs for a new corporate and manufacturing facility in Orlando, Florida.
- Dividends: The company declared a quarterly dividend of $0.17 per share in Q2, consistent with the prior year's regular dividend schedule.
Guidance, Outlook, and Risks
- Outlook: Management expects higher revenue for the remainder of fiscal 2025 compared to 2024, driven by medical device and disposable sales. Operating expenses are also expected to be higher due to sales, marketing, and regulatory costs.
- New Product Launch: The FDA granted 510(k) clearance for the next-generation MRidium 3870 IV infusion pump in May 2025. Strategic rollout to select facilities is planned for Q4 2025, with full commercial distribution expected in 2026.
- Facility Move: Construction of the new facility was completed in early July 2025. The company plans to move operations in Q3 2025, terminating the month-to-month lease at the current location.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025. It includes provisions for immediate expensing of R&D expenditures and increased bonus depreciation. The company is assessing the impact, which is expected to be recorded in Q3 2025 results.
- Risks: Key risks include reliance on a limited number of products, potential supply chain disruptions for sole-sourced components, and regulatory approval delays for future products. The company is also monitoring global trade policies and tariffs.
Investor Verification Checklist
- Verify the timeline and commercial uptake of the newly FDA-cleared MRidium 3870 infusion pump.
- Monitor the completion of the move to the new Orlando facility and the associated final payments (~$1.1 million).
- Assess the financial impact of the OBBBA tax legislation on Q3 2025 results.
- Review the trend in international revenue, which has declined in both Q2 and YTD periods.
- Confirm the status of the IRS examination for the 2021 tax year (closed with no changes as of July 2025).